Having trouble accessing articles? Reset your cache.

Astellas submits mirabegron NDA in Japan

Astellas Pharma Inc. (Tokyo:4503) disclosed in its quarterly financial results that it submitted an NDA in Japan for

Read the full 183 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE